Getting personal about treating HIV

Nature Medicine

Volumn 14, Issue 4, 2008, Pages 369-370

  Neaton, James D ^a   Lane, H Clifford ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

CD4+ T LYMPHOCYTE; CYTOPATHOGENIC EFFECT; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE DEPLETION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TREATMENT RESPONSE; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CC; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; VARIATION (GENETICS);

EID: 41849138607     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0408-369     Document Type: Short Survey

References (11)

1. Ahuja, S.K. et al. Nat. Med. 14, 413-420 (2008).
2. Dolan, M.J. et al. Nat. Immun. 8, 1324-1336 (2007).
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 1-128, 〈http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf〉, accessed 14 March 2008 (Department of Health and Human Services, 29 January 2008).
4. Kuritzkes, D., Kar, S. & Kirkpatrick, P. Nat. Rev. Drug Discov. 7, 15-16 (2008).
5. May, M. et al. AIDS 21, 1185-1197 (2007).
6. Phillips, A.N. et al. AIDS 21, 1717-1721 (2007).
7. Weber, R. et al. Arch. Intern. Med. 166, 1632-1641 (2006).
8. Smit, C. et al. AIDS 20, 741-749 (2006).
9. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N. Engl. J. Med. 355, 2283-2296 (2006).
10. Phillips, A.N. et al. Br. Med. J. 334, 76-78 (2007).
11. Fellay, J. et al. Science 317, 944-947 (2007).